ImmunityBio
IBRX
IBRX
139 hedge funds and large institutions have $256M invested in ImmunityBio in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2.34% more ownership
Funds ownership: 9.87% → 12.21% (+2.3%)
2% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 42
22% less call options, than puts
Call options by funds: $3.69M | Put options by funds: $4.76M
Holders
139
Holding in Top 10
2
Calls
$3.69M
Puts
$4.76M
Top Buyers
| 1 | +$38.6M | |
| 2 | +$6.77M | |
| 3 | +$4.3M | |
| 4 |
BlackRock
New York
|
+$4.07M |
| 5 |
Goldman Sachs
New York
|
+$2.97M |
Top Sellers
| 1 | -$3.37M | |
| 2 | -$2M | |
| 3 | -$1.98M | |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.57M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.06M |